Current price is less than the intrinsic value
Stock has been generating better return on equity than bank FD
Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists, not a lot of promoter holding is pledged and default probability is low
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
Customise key ratios, see detailed forecasts, download stock data and more
In last 6 months, promoter holding in the company has almost stayed constant
In last 3 months, mutual fund holding of the company has almost stayed constant
1 week ago•Moneycontrol
1 week ago•The Hindu Businessline
1 month ago•Moneycontrol
Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
Aurobindo Pharma Limited has informed the Exchange regarding 'We inform you that our wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has on August 29, 2019 entered into an agreement with Shanghai LongJin Investment Company Ltd., China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of ??Longxiang Pharma Taizhou Co Ltd??., for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ??Annexure A??.'.
Interim • Div/Share: ₹ 1.25